Teva Pharmaceutical Industries Ltd (FRA:TEV)
€ 26.7 +1 (+3.89%) Market Cap: 31.09 Bil Enterprise Value: 42.67 Bil PE Ratio: 23.58 PB Ratio: 4.45 GF Score: 57/100

Teva Pharmaceutical Industries Ltd at Bank of America Healthcare Conference Transcript

May 14, 2024 / 03:40PM GMT
Release Date Price: €15.45 (-0.96%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

(technical difficulty)

in your healthcare conference in Las Vegas. I'm pleased to be introducing our next company presenter, Teva Pharmaceuticals. We've got CEO, Richard Francis, and Eric Hughes, Head of Global R&D. My name is Jason Gerberry. I cover SMID-cap biotech and specialty pharma and so gentlemen, thanks for joining.

Questions & Answers

Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

Richard, maybe I'll start with a high-level point. You came on board, you had a Capital Markets Day in May of last year, emphasizing sort of a Pivot to Growth, your predecessor put out a lot of fires, stabilize the base. Then you come in, now that things were -- the foundation was stabilized and you're looking to drive that Pivot to Growth, where do you see since, kind of, laying out that edict about a year ago, the company having progressed? Maybe you just want to highlight those key points and then we'll go from there.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot